Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy

• Published in: Cancers Vol. 14; no. 4; p. 902
• Main Authors: Van Trimpont, Maaike, Peeters, Evelien, De Visser, Yanti, Schalk, Amanda M, Mondelaers, Veerle, De Moerloose, Barbara, Lavie, Arnon, Lammens, Tim, Goossens, Steven, Van Vlierberghe, Pieter
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 11.02.2022; MDPI
• Subjects: Acute lymphoblastic leukemia; Amino acids; Ammonia; Antibodies; Asparaginase; Asparagine; Aspartate-ammonia ligase; Aspartic acid; Bioavailability; Cancer; Cancer therapies; Chemoresistance; Cytotoxicity; E coli; Enzymes; Immunogenicity; Immunology; L-asparaginase; Leukemia; Lymphatic leukemia; Lymphoblasts; Medical prognosis; Neurotoxicity; Pancreatitis; Pediatrics; Review; Side effects; Solid tumors; Toxicity; asparagine; solid cancers; glutamine; acute lymphoblastic leukemia; asparaginase
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14040902

L-Asparaginase (L-ASNase) is an enzyme that hydrolyses the amino acid asparagine into aspartic acid and ammonia. Systemic administration of bacterial L-ASNase is successfully used to lower the bioavailability of this non-essential amino acid and to eradicate rapidly proliferating cancer cells with a high demand for exogenous asparagine. Currently, it is a cornerstone drug in the treatment of the most common pediatric cancer, acute lymphoblastic leukemia (ALL). Since these lymphoblasts lack the expression of asparagine synthetase (ASNS), these cells depend on the uptake of extracellular asparagine for survival. Interestingly, recent reports have illustrated that L-ASNase may also have clinical potential for the treatment of other aggressive subtypes of hematological or solid cancers. However, immunogenic and other severe adverse side effects limit optimal clinical use and often lead to treatment discontinuation. The design of optimized and novel L-ASNase formulations provides opportunities to overcome these limitations. In addition, identification of multiple L-ASNase resistance mechanisms, including ASNS promoter reactivation and desensitization, has fueled research into promising novel drug combinations to overcome chemoresistance. In this review, we discuss recent insights into L-ASNase adverse effects, resistance both in hematological and solid tumors, and how novel L-ASNase variants and drug combinations can expand its clinical applicability.